TAG:
diagnostic assays
Lab Utilization Is Healthcare’s Ticking Time Bomb
By R. Lewis Dark | From the Volume XVI No. 17 – December 14, 2009 Issue
TODAY I WOULD LIKE TO SPEAK TO ONE OF THE ELEPHANTS IN THE LAB INDUSTRY’S ROOM. It is the ticking time bomb of lab utilization. Sometime in the next 36 to 60 months, this time bomb will go off. It will catch both health policy makers and payers unprepared and, the consequences will be corrosive to …
November 02, 2009 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVI No. 15 – November 02, 2009 Issue
Digital microfluidics and lab-on-a-chip technologies are being combined to create a new way to measure breast estrogen levels in women. An interdisciplinary group at the University of Toronto developed a lab-on-a-chip technique to analyze blood and breast tissue to identify women at …
New Lab Player Launches In Breast Cancer Market
By Robert Michel | From the Volume XVI No. 11 – August 10, 2009 Issue
CEO SUMMARY: Having opened its CLIA-licensed laboratory in Huntington Beach, California, Agendia, Inc., becomes the newest competitor to enter the market for breast cancer testing. Its proprietary assay looks at 70 genes to assess the risk of recurrence. The company expects to co…
Lab M&A Deals in June Show Market Direction
By Robert Michel | From the Volume XVI No. 10 – July 20, 2009 Issue
CEO SUMMARY: Despite a dismal economy, the month of June spawned two interesting merger/acquisition transactions in the lab testing industry. In one case, a blood brother gobbled up a specialty diagnostics company. In another transaction, two cross-town neighbors in Kansas City m…
Need Rigorous Validation For Home Brew Assays
By Robert Michel | From the Volume XVI No. 3 – February 23, 2009 Issue
CEO SUMMARY: National headlines about erroneous Vitamin D results are a reminder to the lab industry of the imprecision and risks associated with home brew testing. According to one laboratory expert, every laboratory-developed test (LDT) must meet two high standards. On…
Rapid Genome Sequencing Predicted by Mid-2009
By Robert Michel | From the Volume XV No. 14 – October 20, 2008 Issue
CEO SUMMARY: In the same way that the Human Genome Project was disrupted by the entry of C. Craig Venter and Perkin-Elmer in what was then a 15-year, $3 billion project, now Complete Genetics of Mountain View, California, is disrupting the race to the $1,000 human genome sequence. Develop…
NY & Calif. Act to Stop Web Gene Testing Firms
By Robert Michel | From the Volume XV No. 9 – July 7, 2008 Issue
CEO SUMMARY: Events in the past month indicate that a war is developing between Internet-based companies offering genetic tests to consumers and state and federal health regulators. New York state authorities have sent letters to at least 31 such companies in recent month…
March 24, 2008 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XV No. 4 – March 24, 2008 Issue
Things are happening under new ownership and management at DCL Medical Laboratories LLC., based in Indianapolis, Indiana. DCL announced a strategic partnership with Third Wave Technologies Inc., a molecular diagnostics company in Madison, Wisconsin. In the partnershi…
Growing NeoGenomics Offers FISH Test TC/PC
By Robert Michel | From the Volume XIV No. 10 – July 16, 2007 Issue
CEO SUMMARY: This specialty lab testing company now has laboratories in Fort Meyers, Florida; Nashville, Tennessee; and Irvine, California. It recently beefed up its executive ranks and is adding to its menu of genetic and molecular assays. In December, 2006, NeoGenomics …
Inverness Buys Biosite, Has New Venture with P&G
By Robert Michel | From the Volume XIV No. 8 – June 4, 2007 Issue
CEO SUMMARY: On the same day that Inverness Medical Innovations announced that it would acquire Biosite, thus beating out Beckman Coulter in the bidding war for Biosite, Inverness also announced that it had entered into a joint venture with Procter & Gamble. Together, the two companie…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized